Sartorius Stedim BiotechCHIX:DIMP 84 Operating Margin % is 19.61% as of Mar. 2026, which is 17% below its 10-year median of 23.49. GuruFocus rates CHIX:DIMP with a GF Score™ of 84/100 and a GF Value™ of €207.88 (Modestly Undervalued). The stock has 5 warning signs investors should review. Among 816 Medical Devices & Instruments companies, Sartorius Stedim Biotech ranks better than 83.33% on this metric.
Sartorius Stedim Biotech SA operating margin has been in a 5-year decline. The average rate of decline per year is -12.6%.
The historical rank and industry rank for Sartorius Stedim Biotech's Operating Margin % or its related term are showing as below:
CHIX:DIMp'
s Operating Margin % Range Over the Past 10 Years
Min: 14.3 Med: 23.49 Max: 30.59
Current: 18.34
CHIX:DIMp's Operating Margin % is ranked better than 83.33% of 816
companies
in the Medical Devices & Instruments industry
Industry Median: 3.465
vs CHIX:DIMp: 18.34
Just like Gross Margin %, it is important to see a company maintains its operating margin over time. Among the same industry, a company with higher operating margin is more efficient in its operation. It is also more stable during industry slowdown or recessions. Peter Lynch prefers those with higher margins than those with lower margins.
Be Aware
Operating Margin % can be manipulated by adjusting the rate of depreciation, depletion and amortization (DDA).
If a company is facing competition, its Operating Margin % may decline. Often the Operating Margin % declines well before the company's Revenue or even profit decline. Therefore, Operating Margin % is a very important indicator of whether the company is facing problems.
For instance, by 2012, Nokia (NOK)'s problems were well known and its stock had lost more than 90% of its market value since 2007. But Nokias Operating Margin % had already been in decline since 2002, although its Earnings per Share (Diluted) were still rising. Investors who paid attention to Operating Margin % would have avoided this huge loss. The same can be said for Research-in-Motion (RIMM).
Therefore, Operating Margin % is a very important screening filter for GuruFocus. GuruFocus's Buffett-Munger screener requires that the profit margin is either consistent or expanding. The Model Portfolio of the Buffett-Munger screener has outperformed the market every year since inception in 2009.
Sartorius Stedim Biotech Operating Margin % Related Terms
Sartorius Stedim Biotech Operating Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CHIX:DIMP vs ISRG, BDX, MDLN: Operating Margin % Comparison
For the Medical Instruments & Supplies subindustry, Sartorius Stedim Biotech's Operating Margin %, along with its competitors' market caps and Operating Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sartorius Stedim Biotech Operating Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Sartorius Stedim Biotech's Operating Margin % distribution charts can be found below:
* The bar in red indicates where Sartorius Stedim Biotech's Operating Margin % falls into.
Operating Margin % - also known as operating income margin, operating profit margin and return on sales (ROS) - is the ratio of Operating Income divided by net sales or Revenue, usually presented in percent.
Sartorius Stedim Biotech's Operating Margin % for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sartorius Stedim Biotech (CHIX:DIMP) has a Operating Margin % of 19.61% as of Mar. 2026. Operating margin is the ratio of total operating income to net sales. View historical data on Sartorius Stedim Biotech and its competitors. This is 17% below median its historical median of 23.49. Over the past decade, Sartorius Stedim Biotech's Operating Margin % has ranged from 14.30 to 30.59. According to the industry distribution chart, Sartorius Stedim Biotech ranks #136 out of 816 companies in the Medical Devices & Instruments industry, placing it in the top 16.7%.
Is Sartorius Stedim Biotech's Operating Margin % too high?
Sartorius Stedim Biotech's current Operating Margin % of 19.61% is 17% below median its 10-year median of 23.49. Over the past 10 years, this metric has ranged from a low of 14.30 to a high of 30.59. The Medical Devices & Instruments industry median Operating Margin % is 3.47. Sartorius Stedim Biotech's value of 19.61% is 465.9% above this industry median. Based on the distribution chart, Sartorius Stedim Biotech ranks #136 out of 816 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Sartorius Stedim Biotech has a GF Score™ of 84/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sartorius Stedim Biotech's Operating Margin % compare to ISRG and BDX?
According to the Medical Devices & Instruments industry distribution chart, Sartorius Stedim Biotech ranks #136 out of 816 companies for Operating Margin %. This places Sartorius Stedim Biotech in the top 17% of its industry — outperforming the majority of peers. The industry median Operating Margin % is 3.47. Sartorius Stedim Biotech's value of 19.61% is 465.9% above this benchmark. Historically, Sartorius Stedim Biotech's own Operating Margin % has ranged from 14.30 to 30.59 over the past decade. While the company's 10-year median is 23.49 vs. the industry median of 3.47, Sartorius Stedim Biotech has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Operating Margin % for a Medical Devices & Instruments company?
The median Operating Margin % among Medical Devices & Instruments companies is 3.47, based on 816 companies in the industry. Companies in the top quartile (top 25%) have a Operating Margin % significantly above this median, while those in the bottom quartile fall well below. However, Operating Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Sartorius Stedim Biotech's current Operating Margin % of 19.61% is 465.9% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Operating Margin % mean?
A high Operating Margin % can signal that a stock is expensive relative to its fundamentals. Operating margin is the ratio of total operating income to net sales. View historical data on Sartorius Stedim Biotech and its competitors. For the Medical Devices & Instruments industry, the median Operating Margin % is 3.47 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Sartorius Stedim Biotech's current Operating Margin % is 19.61%, which is 17% below median its own 10-year median of 23.49. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sartorius Stedim Biotech stock overvalued right now?
Based on GuruFocus' analysis, Sartorius Stedim Biotech (CHIX:DIMP) is currently considered Modestly Undervalued. The stock's GF Value™ is €207.88, compared to a current price of €162.10 — trading 22% below its estimated fair value. The current Operating Margin % is 19.61%, which is 17% below median its 10-year median of 23.49 and 465.9% above the Medical Devices & Instruments industry median of 3.47. Sartorius Stedim Biotech's overall GF Score™ is 84/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Operating Margin % calculated?
Operating Margin % is calculated from a company's financial statements. For Sartorius Stedim Biotech (CHIX:DIMP), the current Operating Margin % is 19.61% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sartorius Stedim Biotech (CHIX:DIMP) Overvalued in 2026?
Based on GuruFocus' analysis, Sartorius Stedim Biotech stock appears to be undervalued.
The current stock price of €162.10 is trading 22% below its estimated GF Value™ of €207.88.
GuruFocus considers Sartorius Stedim Biotech to be Modestly Undervalued.
Key valuation signals for CHIX:DIMP:
Operating Margin %: 19.61% (17% below median its 10-year median of 23.49)
GF Value™: €207.88 vs. price of €162.10 (22% below fair value)
Industry Position: 465.9% above the Medical Devices & Instruments median (#136 of 816)
No single metric tells the full story. See the CHIX:DIMP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sartorius Stedim Biotech is a leading provider of bioprocessing solutions. It sells equipment and consumables for fermentation, filtration, fluid management, purification, and cell culture media for manufacturing biologic drugs and has a focus on single-use technology. It is a subsidiary of Sartorius AG, which has 71.5% ownership and 83% voting control. The business is geographically diverse, with 35% of sales from the Americas, 42% from Europe, the Middle East, and Africa, 15% from Asia excluding China, and 8% from China.
84GF Score
Get the complete analysis for CHIX:DIMP
Operating Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CHIX:DIMP has been successfully added to your 
